Louisiana State Employees Retirement System Sells 1,700 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

Louisiana State Employees Retirement System cut its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 1.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 119,200 shares of the company’s stock after selling 1,700 shares during the quarter. Louisiana State Employees Retirement System’s holdings in Roivant Sciences were worth $1,410,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Creative Planning lifted its holdings in Roivant Sciences by 47.5% in the 3rd quarter. Creative Planning now owns 23,541 shares of the company’s stock worth $272,000 after buying an additional 7,579 shares during the period. BTS Asset Management Inc. bought a new position in shares of Roivant Sciences during the third quarter valued at approximately $450,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Roivant Sciences by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,747 shares of the company’s stock worth $307,000 after acquiring an additional 4,692 shares during the period. State of Alaska Department of Revenue boosted its holdings in Roivant Sciences by 37.0% in the third quarter. State of Alaska Department of Revenue now owns 50,675 shares of the company’s stock valued at $584,000 after acquiring an additional 13,675 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in Roivant Sciences by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 142,234 shares of the company’s stock valued at $1,641,000 after purchasing an additional 55,445 shares during the period. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Insider Buying and Selling

In other news, COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $11.32, for a total value of $1,132,000.00. Following the sale, the chief operating officer now owns 606,525 shares of the company’s stock, valued at $6,865,863. The trade was a 14.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CIO Mayukh Sukhatme sold 185,946 shares of the business’s stock in a transaction dated Tuesday, December 24th. The stock was sold at an average price of $12.00, for a total transaction of $2,231,352.00. Following the sale, the executive now directly owns 18,836,547 shares in the company, valued at approximately $226,038,564. This represents a 0.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 2,160,670 shares of company stock valued at $25,306,474 in the last ninety days. Company insiders own 7.90% of the company’s stock.

Wall Street Analyst Weigh In

ROIV has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research report on Tuesday, February 11th. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $18.08.

Roivant Sciences Stock Up 1.1 %

Shares of ROIV opened at $10.56 on Monday. Roivant Sciences Ltd. has a twelve month low of $9.76 and a twelve month high of $13.06. The company has a 50 day moving average of $11.34 and a two-hundred day moving average of $11.59. The company has a market cap of $7.69 billion, a price-to-earnings ratio of 1.87 and a beta of 1.25.

Roivant Sciences (NASDAQ:ROIV) last released its earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a net margin of 3,827.42% and a negative return on equity of 14.65%. On average, sell-side analysts expect that Roivant Sciences Ltd. will post -1.19 EPS for the current year.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.